BioTime Inc (BTX)-Medical Equipment-Deals and Alliances Profile

BioTime Inc (BTX)-Medical Equipment-Deals and Alliances Profile


  • Products Id :- GDME225D
  • |
  • Pages: 58
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

BioTime Inc (BioTime) is a biotechnology company which focuses on regenerative medicine and plasma volume expanders. The company's Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. The company is also developing Renevia to facilitate cell transplantation; AST-VAC1 and AST-VAC2 autologous (patient-specific) cancer vaccine; Premvia for tendon and wound-management applications; OpRegen for the treatment of dry form of age-related macular degeneration (AMD); AST-OPC1 for spinal cord injury rehabilitation; HyStem hydrogel products; and mobile health software products. The company's products can be used in oncology, neuroscience, orthopedics and blood and vascular diseases. The company's products are developed on its pluripotent stem technology. The company has operations in the US, Hong Kong, Israel and Singapore. BioTime is headquartered in California, the US.

BioTime Inc (BTX)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company financial deals that enable you to understand the company expansion/divestiture and fund requirements

The profile enables you to analyze the company financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company business segments' expansion / divestiture strategy

The profile presents deals from the company core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

BioTime Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5

BioTime Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7

BioTime Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8

BioTime Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9

BioTime Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10

BioTime Inc, Medical Equipment, Deal Details 12

Venture Financing 12

LifeMap Solutions Raises US$5 Million In Seed Financing 12

Partnerships 12

OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx 12

OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test 13

OncoCyte Expands Co-Development Agreement with Wistar Institute 14

BioTime Enters Into Distribution Agreement With USCN Life Science 14

Heraeus Medical Enters into Licensing Agreement with OrthoCyte 15

OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology 16

Biotime Amends Licensing Agreement With University of Utah 17

BioTime Enters Into Option Licensing Agreement With USCN Life Science 18

Equity Offering 19

Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 19

BioTime to Raise up to USD25 Million in Private Placement of Shares 20

OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 21

OncoCyte Raises USD3.2 Million in Private Placement of Units 22

OncoCyte Raises USD7.3 Million in Private Placement of Units 23

BioTime Raises USD5 Million in Private Placement of Shares 25

BioTime Raises USD20.4 Million in Private Placement of Shares 26

OncoCyte Raises USD3.3 Million in Private Placement of Shares 27

BioTime Completes Private Placement Of Shares For US$6.4 Million 27

BioTime Announces Public Offering Of Shares For Up To US$15 Million 28

BioTime Completes Public Offering Of Shares For US$3.5 Million 29

BioTime Completes Private Placement Of Units For US$9 Million 30

BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 31

BioTime Announces Private Placement Of Common Stock 33

BioTime Completes Private Placement For US$3.6 Million 33

Acquisition 34

OrthoCyte Completes Acquisition Of Glycosan BioSystems 34

BioTime Inc-Key Competitors 36

Key Employees 37

Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 40

Financial Announcements 40

May 10, 2017: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 40

Mar 16, 2017: BioTime Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments 42

Feb 21, 2017: BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary 45

Nov 03, 2016: BioTime Reports Third Quarter Results and Recent Clinical Progress 46

Aug 09, 2016: BioTime Reports Second Quarter Results and Recent Corporate Accomplishments 48

May 10, 2016: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 50

Corporate Communications 53

Feb 07, 2017: BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel 53

Oct 31, 2016: BioTime Appoints Industry Veteran Jim Knight as Senior Vice President, Head of Corporate Development 54

Product News 55

May 11, 2017: BioTime Presents Retinal Restoration Data at ARVO 55

Aug 15, 2016: BioTime Announces Issuance of 31 New Patents to Strengthen its Patent Portfolio in Regenerative Medicine 56

Jun 28, 2016: Mount Sinai Launches Mobile Healthcare App Developed with LifeMap Solutions, a subsidiary of BioTime 57

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58

List of Figures

BioTime Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 1

BioTime Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 1

BioTime Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 1

BioTime Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 1

BioTime Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6

BioTime Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 7

BioTime Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8

BioTime Inc, Medical Equipment, Deals by Market, 2011 to YTD 2017 9

List of Tables

BioTime Inc, Medical Equipment, Key Facts, 2016 1

BioTime Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 1

BioTime Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6

BioTime Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7

BioTime Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8

BioTime Inc, Deals By Market, 2011 to YTD 2017 9

BioTime Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10

LifeMap Solutions Raises US$5 Million In Seed Financing 12

OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx 12

OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test 13

OncoCyte Expands Co-Development Agreement with Wistar Institute 14

BioTime Enters Into Distribution Agreement With USCN Life Science 14

Heraeus Medical Enters into Licensing Agreement with OrthoCyte 15

OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology 16

Biotime Amends Licensing Agreement With University of Utah 17

BioTime Enters Into Option Licensing Agreement With USCN Life Science 18

Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 19

BioTime to Raise up to USD25 Million in Private Placement of Shares 20

OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 21

OncoCyte Raises USD3.2 Million in Private Placement of Units 22

OncoCyte Raises USD7.3 Million in Private Placement of Units 23

BioTime Raises USD5 Million in Private Placement of Shares 25

BioTime Raises USD20.4 Million in Private Placement of Shares 26

OncoCyte Raises USD3.3 Million in Private Placement of Shares 27

BioTime Completes Private Placement Of Shares For US$6.4 Million 27

BioTime Announces Public Offering Of Shares For Up To US$15 Million 28

BioTime Completes Public Offering Of Shares For US$3.5 Million 29

BioTime Completes Private Placement Of Units For US$9 Million 30

BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 31

BioTime Announces Private Placement Of Common Stock 33

BioTime Completes Private Placement For US$3.6 Million 33

OrthoCyte Completes Acquisition Of Glycosan BioSystems 34

BioTime Inc, Key Competitors 36

BioTime Inc, Key Employees 37

BioTime Inc, Subsidiaries 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

BioTime Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16190
Site License
USD 500 INR 32380
Corporate User License
USD 750 INR 48570

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com